Notable Movers: Kohl's Corporation, Celgene Corporation, Ariad Pharmaceuticals, Alexion Pharmaceuticals

Lakeway, TX -- (SBWIRE) -- 02/20/2013 -- vb-news.net, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Kohl's Corporation (NYSE:KSS) stock gained 1.91% to $47.37. The company last week invites customers to join the fight against breast cancer this spring with a new collection from the Kohl's Cares® cause merchandise program.

Additionally, analysts at Maxim Group initiated coverage on shares of Kohls Corp (NYSE: KSS) in a research report issued to clients and investors on Feb. 12. The firm set a “hold” rating and a $48.50 price target on the stock.

How Should Investors Trade KSS After The Solid Jump? Let’s Find Out Here

Celgene Corporation (NASDAQ:CELG) shares jumped 2.53% to $103. The company announced today that it has entered into an accelerated share repurchase (ASR) agreement with an investment bank to repurchase an aggregate of $600 million of the company's common stock. The ASR is part of the existing Board authorized share repurchase program. Year-to-date, Celgene has repurchased approximately $385 million of its common stock and has approximately $1,450 million remaining in the existing program. Celgene has repurchased approximately $5,050 million of its common stock over the last four years.

Is CELG Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares climbed 1.14% to $21.26. The company announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Tuesday, February 26, at 9:00 a.m. (ET).

Is ARIA Buy After The Recent Price Movement? Find Out Here

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares increased 1.56% to $84.69. The company, last week, announced financial results for the quarter and year ended December 31, 2012. For the three months ended December 31, 2012, the company reported net product sales of Soliris® (eculizumab) of $320.5 million, compared to $227.6 million for the same period in 2011. The Company reported non-GAAP net income of $122.3 million, or $0.60 per share in Q4 2012, compared to non-GAAP net income of $80.5 million, or $0.41 per share, in Q4 2011.

Is ALXN a Buy At The Current Market Price? Don’t Miss Out Our Special Coverage Here

About vb-news.net
vb-news.net’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by vb-news.net is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vb-news.net does expect that investors will buy and sell securities based on information assembled and presented in vb-news.net. PLEASE always do your own due diligence, and consult your financial advisor.